^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug Class:PARP inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative

    Published date:
    07/29/2021
    Excerpt:
    Patients with HR-positive MBC with germline BRCA mutations no longer benefiting from endocrine therapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy.
    DOI:
    10.1200/JCO.21.01374